Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Here is What Hedge Funds Think About Solar Capital Ltd. (SLRC)

Page 1 of 2

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in these filings, which are based on their September 30 holdings, data that is available nowhere else. Should you consider Solar Capital Ltd. (NASDAQ:SLRC) for your portfolio? We’ll look to this invaluable collective wisdom for the answer.

Is Solar Capital Ltd. (NASDAQ:SLRC) undervalued? Investors who are in the know are turning less bullish. The number of long hedge fund positions decreased by 3 recently. Solar Capital Ltd. (NASDAQ:SLRC) was in 14 hedge funds’ portfolios at the end of September. There were 17 hedge funds in our database with Solar Capital Ltd. (NASDAQ:SLRC) holdings at the end of the previous quarter. The stock performance of the company was in alignment with the hedge fund behavior, with its stock losing 12.11% value throughout the quarter. We will discuss more about hedge funds that held positions in Solar Capital Ltd. (NASDAQ:SLRC), at the end of the previous quarter.

The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity, but it may still be less popular than similarly priced stocks. That’s why at the end of this article, we will examine companies such as Team, Inc. (NYSE:TISI), Live Oak Bancshares Inc (NASDAQ:LOB), and Gigamon Inc (NYSE:GIMO) to gather more data points.

Follow Solar Capital Ltd. (NASDAQ:SLRC)
Trade (NASDAQ:SLRC) Now!

In the 21st century investor’s toolkit, there are tons of gauges stock market investors use to assess their holdings. A couple of the best gauges are hedge fund and insider trading signals. Our researchers have shown that, historically, those who follow the top picks of the elite money managers can outpace the broader indices by a very impressive margin (see the details here).

Keeping this in mind, we’re going to analyze the fresh action regarding Solar Capital Ltd. (NASDAQ:SLRC).

What have hedge funds been doing with Solar Capital Ltd. (NASDAQ:SLRC)?

At the end of Q3, a total of 14 of the hedge funds tracked by Insider Monkey held long positions in this stock, a decline of 18% from one quarter earlier. With the smart money’s sentiment swirling, there exists a select group of noteworthy hedge fund managers who were increasing their holdings meaningfully (or already accumulated large positions).

According to Insider Monkey’s hedge fund database, Charles Clough’s Clough Capital Partners has the most valuable position in Solar Capital Ltd. (NASDAQ:SLRC), worth close to $7.1 million, corresponding to 0.3% of its total 13F portfolio. Sitting at the No. 2 spot is Cloud Gate Capital, led by Brian Newman and David Heller, holding a $6.3 million position; 3.1% of its 13F portfolio is allocated to the company. Other peers that are bullish contain Brian Ashford-Russell and Tim Woolley’s Polar Capital, Israel Englander’s Millennium Management, and Ken Griffin’s Citadel Investment Group.

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!